Distinguished in Ovarian Carcinosarcoma

Dr. Russell J. Schilder

Oncology
925 Chestnut St, Suite 320a, 
Philadelphia, PA 
Distinguished in Ovarian Carcinosarcoma
925 Chestnut St, Suite 320a, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Russell Schilder is an Oncologist in Philadelphia, Pennsylvania. Dr. Schilder is rated as a Distinguished provider by MediFind in the treatment of Ovarian Carcinosarcoma. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Cervical Cancer, and Virilizing Ovarian Tumor.

His clinical research consists of co-authoring 45 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Specialist in PA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO

Locations

925 Chestnut St, Suite 320a, Philadelphia, PA 19107

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently With Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer
Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently With Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer
Enrollment Status: Completed
Publish Date: November 12, 2025
Intervention Type: Radiation, Drug
Study Drugs: Atezolizumab, Cisplatin
Study Phase: Phase 1
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers)
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers)
Enrollment Status: Terminated
Publish Date: September 22, 2025
Intervention Type: Drug
Study Drugs: STRO-002, Bevacizumab
Study Phase: Phase 1
Phase 2 Study of M6620 (VX-970) in Combination With Gemcitabine Versus Gemcitabine Alone in Subjects With Platinum-Resistant Recurrent Ovarian or Primary Peritoneal Fallopian Tube Cancer
Phase 2 Study of M6620 (VX-970) in Combination With Gemcitabine Versus Gemcitabine Alone in Subjects With Platinum-Resistant Recurrent Ovarian or Primary Peritoneal Fallopian Tube Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 26, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers
Enrollment Status: Completed
Publish Date: August 20, 2025
Intervention Type: Drug
Study Drug: STRO-002
Study Phase: Phase 1
Evaluation of the Addition of N-Acetylcysteine to Topotecan in the Tumor Microenvironment of Persistent or Recurrent High Grade Endometrioid or Serous Ovarian Carcinoma
Evaluation of the Addition of N-Acetylcysteine to Topotecan in the Tumor Microenvironment of Persistent or Recurrent High Grade Endometrioid or Serous Ovarian Carcinoma
Enrollment Status: Terminated
Publish Date: May 04, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Phase Ib/II Study of CRLX101 in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Phase Ib/II Study of CRLX101 in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Enrollment Status: Terminated
Publish Date: May 28, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 8 Less Clinical Trials

45 Total Publications

Image guided brachytherapy quality assurance on NRG GY017 investigating immunotherapy in addition to chemoradiation for locally advanced cervical cancer.
Image guided brachytherapy quality assurance on NRG GY017 investigating immunotherapy in addition to chemoradiation for locally advanced cervical cancer.
Journal: Brachytherapy
Published: April 04, 2025
Similar Doctors
Distinguished in Ovarian Carcinosarcoma
Dr. Mark S. Shahin
Oncology
Distinguished in Ovarian Carcinosarcoma
Dr. Mark S. Shahin
Oncology

Alliance Cancer Specialists Doylestown

599 West State Street, Suite 312, 
Doylestown, PA 
 (24.6 miles away)
800-789-7366
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mark Shahin is an Oncologist in Doylestown, Pennsylvania. Dr. Shahin is rated as an Elite provider by MediFind in the treatment of Ovarian Carcinosarcoma. His top areas of expertise are Endometrial Cancer, Ovarian Cancer, Cervical Cancer, Lymphadenectomy, and Bladder Reconstruction. Dr. Shahin is currently accepting new patients.

Distinguished in Ovarian Carcinosarcoma
Dr. Lainie P. Martin
Oncology
Distinguished in Ovarian Carcinosarcoma
Dr. Lainie P. Martin
Oncology

Jordan Center For Gynecologic Cancers

3400 Civic Center Boulevard, West Pavilion, 3rd Floor, 
Philadelphia, PA 
 (1.9 miles away)
800-789-7366
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lainie Martin is an Oncologist in Philadelphia, Pennsylvania. Dr. Martin is rated as a Distinguished provider by MediFind in the treatment of Ovarian Carcinosarcoma. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Virilizing Ovarian Tumor, and Ovarian Carcinosarcoma. Dr. Martin is currently accepting new patients.

Distinguished in Ovarian Carcinosarcoma
Dr. Mark A. Morgan
Oncology
Distinguished in Ovarian Carcinosarcoma
Dr. Mark A. Morgan
Oncology

Jordan Center For Gynecologic Cancers

3400 Civic Center Boulevard, West Pavilion, 3rd Floor, 
Philadelphia, PA 
 (1.9 miles away)
800-789-7366
Languages Spoken:
English
See accepted insurances

Mark Morgan is an Oncologist in Philadelphia, Pennsylvania. Dr. Morgan is rated as a Distinguished provider by MediFind in the treatment of Ovarian Carcinosarcoma. His top areas of expertise are Endometrial Cancer, Malignant Mixed Mullerian Tumor, Ovarian Carcinosarcoma, and Sertoli-Leydig Cell Tumor.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Schilder's expertise for a condition
ConditionClose
View All 11 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile